Informed Prostate Cancer Patient Support

FDA Panel: Thumbs Down for Prostate Cancer Focal Therapy | MedPage Today : Votes 13-2 against novel photodynamic therapy

New study compares long-term side effects from different prostate cancer treatments - Harvard Health Blog - Harvard Health Publishing : Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal …

Variation in Inter-institutional Plan Quality When Adopting A Hypofractionated Protocol for Prostate Cancer External Beam Radiation Therapy - International Journal of Radiation Oncology • Biology • Physics : This study quantified plan quality differences across the four cancer centers in XXX(blinded for review) for plans that followed the PROstate Fractionated Irradiation Trial (PROFIT) protocol.

Neoadjuvant and Adjuvant ADT With Dose-Escalated PRT Show Similar Outcomes in Prostate Cancer : Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy - European Urology Oncology : Recurrent metastatic prostate cancer is frequently detected with prostate-specific membrane antigen positron emission tomography in men treated with radiotherapy, before meeting the Phoenix criteria for biochemical recurrence. These compelling findings call for re-evaluation of the Phoenix criteria, as timely detection of recurrences might refine salvage and/or adjuvant therapies.

Why Don't We Have Robot Surgeons Yet? | Design News : Robotic-assisted surgery has been around for decades. But how long until your next surgeon is a machine?

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy : Previous trial results showed signficant improvements in radiographic PFS and OS from adding apalutamide to ADT. The FDA recently approved the drug for metastatic castration-sensitive prostate cancer.

Debating the Value of PSA Prostate Screening - The New York Times : In many men identified as having prostate cancer following PSA screening, the disease is neither aggressive nor likely to kill them before something else does.

Less Frequent Prostate Cancer Screening: Good Idea? | Medpage Today : PSA testing pioneer warns about overdiagnosis-mortality trade-off

Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial - ScienceDirect : To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with l…

Treatment Intensification in High-Risk Prostate Cancer: Lessons From the TROG 03.04 RADAR Trial - International Journal of Radiation Oncology • Biology • Physics : Thousands of men across the world have participated in randomized clinical trials testing the role of hormone therapy in the curative treatment of localized, high-risk prostate cancer. Over several decades, we have established that long-term hormone therapy improves survival, even in the setting of dose-escalated external beam radiation therapy (EBRT).1 Recently reported clinical trials suggest that for some men 18 months of hormone therapy may be a suitable duration that balances treatment efficacy with quality-of-life preservation.

Overall survival and second primary malignancies in men with metastatic prostate cancer : Background Among prostate cancer (PC) patients, over 90% of distant metastases occur in the bone. PC treatments may be associated with side effects, including second primary malignancies (SPM). There is limited information on the incidence of SPM among men with bone metastatic PC (mPC) and among men with bone metastatic castration-resistant PC (mCRPC). We estimated overall survival and the incidence of SPM in men with mPC and mCRPC. Methods In the Prostate Cancer data Base Sweden, the National Prostate Cancer Register was linked to other national health care registers, 15,953 men with mPC in 1999–2011 were identified. Further, 693 men with mCRPC were identified. Outcomes were evaluated using stratified incidence rates, Kaplan-Meier estimators and Cox models. Results The mean age among men with mPC was 73.9 years and in men with mCRPC 70.0 years. The median respective survivals were 1.5 (13,965

Prostate Cancer: What It's Like to Have a Prostatectomy | Best Life : "My doctor said I had two options to tackle my prostate cancer: radiation therapy or what he called 'the gold standard.' It didn't take long to decide."

Prostate Cancer PATIENT & CAREGIVER Conference Tickets, Sat, Mar 21, 2020 at 8:00 AM | Eventbrite : Eventbrite - Jan Manarite, Joel Nowak, and Cancer ABCs presents Prostate Cancer PATIENT & CAREGIVER Conference - Saturday, March 21, 2020 at The Brownwood Hotel & Spa, The Villages, FL. Find event and ticket information.

Optimal mCRPC Drug Sequences Emerging - Renal and Urology News : Recent studies provide guidance on which drugs should be used first to obtain the best outcomes.

Areas of consensus at APCCC last year … see Table 1 | THE "NEW" PROSTATE CANCER INFOLINK : So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. This was always going to be a “dense” paper, …

Another Year Older, Another Year Better! | Prostate Cancer Foundation : Welcome to 2020!  It’s the Chinese year of the Rat – the first in the 12-year rotation of zodiac signs, which means that this is a year of renewal.  What better way to start fresh than to make a few simple changes – so you can feel better and look forward to a healthier, happier, …

Hypofractionated Radiation in Prostate Cancer Stands Test of Time : For localized prostate cancer, a hypofractionated radiotherapy regimen that cuts treatment time in half continues to have noninferior efficacy long-term relative to a conventional radiotherapy regimen.

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial | Cancer Biomarkers | JAMA Network Open | JAMA Network : This secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial estimates the long-term risk of any prostate cancer and clinically significant prostate cancer associated with baseline prostate-specific antigen (PSA) levels among men aged 55 to 60 years.

Problematic PSA . . . and other stories | The BMJ : The problem with prostate specific antigen screening (PSA) is selecting a cut-off that provides adequate sensitivity without leading to the over diagnosis of cancers that are unlikely to cause harm. A re-analysis of data from a large trial in the US finds that men aged 55 to 60 whose PSA was less than 2 ng/ml at initial testing were very unlikely to develop clinically significant prostate cancer over 13 years of follow-up ( JAMA Netw Open doi:10.1001/jamanetworkopen.2019.19284). The investigators hope this could improve PSA testing in younger men if those with low baseline PSA levels were classified …

Emsella for Urinary Incontinence San Francisco | Usha Rajagopal, MD : San Francisco Plastic Surgery and Laser Center: Emsella for Urinary Incontinence San Francisco | Usha Rajagopal, MD

Incontinence 101: Fact vs. Fiction : Did you know that urinary incontinence doesn't just impact older adults? Learn more common myths and helpful tips to combat it.

FDA approves new treatment options for 'Emsella' medical chair | WKRC : CINCINNATI (WKRC) - In addition to treatment for women's urinary incontinence issues, the FDA has now approved the use of the 'Emsella' medical chair for men's urinary incontinence. The chair, called the 'B. T. L. Emsella', offers a new non-surgical treatment for these kinds of issues and works to lift the pelvic floor by forcing what feels like intense Kegel exercises. Past user Julie claimed that after just a few treatments, she was getting up a lot less often to go to the bathroom.

BTL Emsella - A Breakthrough Treatment for Incontinence and Confidence : BTL Emsella - A Breakthrough Treatment for Incontinence and Confidence. This unique technology revolutionizes the women’s intimate health and wellness category by providing those suffering from incontinence with a completely non-invasive option.

Stress Urinary Incontinence: BTL EMSELLA Active treatment vs BTL EMSELLA Sham Treatment : High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercise over 28 minutes, with the intention of increasing neuromuscular tone of the pelvic floor. This study will have looking at treatment of the two of the most common pelvic floor disorders: stress or stress predominant urinary incontinence and urge or urge predominant urinary incontinence.

Increased Genetic Screening May Lead to Earlier Prostate Cancer Diagnoses : William L. Dahut, MD, discusses the natural history trial, the implications of the PROfound study, and the importance of screening for men at a high risk for developing prostate cancer.

Copy number alterations are associated with metastatic-lethal progression in prostate cancer | Prostate Cancer and Prostatic Diseases : Aside from Gleason score few factors accurately identify the subset of prostate cancer (PCa) patients at high risk for metastatic progression. We hypothesized that copy number alterations (CNAs), assessed using CpG methylation probes on Illumina Infinium® Human Methylation450 (HM450K) BeadChip arrays, could identify primary prostate tumors with potential to develop metastatic progression. Epigenome-wide DNA methylation profiling was performed in surgically resected primary tumor tissues from two cohorts of PCa patients with clinically localized disease who underwent radical prostatectomy (RP) as primary therapy and were followed prospectively for at least 5 years: (1) a Fred Hutchinson (FH) Cancer Research Center-based cohort (n = 323 patients); and (2) an Eastern Virginia (EV) Medical School-based cohort (n = 78 patients). CNAs were identified using t

Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s) : Clinical Trials - clinicaltrials.gov Significant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In partic...

Revisiting Immunotherapy: A Focus on Prostate Cancer | Cancer Research : Therapeutic interventions to harness the immune system against tumor cells have provided mixed results in the past for several solid tumors and hematologic malignancies. However, immunotherapy has advanced considerably over the last decade and is becoming an integral combination for treating patients with advanced solid tumors. In particular, prostate cancer (PCa) immunotherapy has shown modest efficacy for patients in the past. With several key discoveries on immune mechanisms and advanced molecular diagnostic platforms recently, immunotherapy is re-emerging as a viable option for PCa, especially castration-resistant prostate cancer (CRPC), to stimulate anti-tumor immunity. Combination of patient-tailored immunotherapy and immune checkpoint blockers with conventional cytotoxic agents and androgen receptor (AR)-targeted therapies should move the field forward. With a recent adaptation that the application of immun

Breaking Ground in GU Cancers | Page 2 : Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy : Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.

Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study : Objectives To examine and compare changes in strength and physical function from pre- to post-diagnosis among men with prostate cancer (PC, [cases]) and matched non-cancer controls identified from the Health, Aging and Body Composition (Health ABC) study. Materials and methods We conducted a longitudinal analysis of 2 strength and 3 physical function-based measures among both cases and controls, identified from a large cohort of community living older adults enrolled in the Health ABC study. We plotted trajectories for each measure and compared cases vs. controls from the point of diagnosis onwards using mixed-effects regression models. For cases only, we examined predictors of poor strength or physical function. Results We identified 117 PC cases and 453 matched non-cancer controls (50% African Americans). At baseline, there were no di

On The Horizon – A Treatment for Very Advanced Prostate Cancer — Cancer ABCs : At ASCO- GU there was an interim data release from the LuPIN phase I/II clinical trial that holds great promise for men who have end-stage prostate cancer. The data analyzed the survival benefit of 32 men with end stage prostate cancer who were treated with the combination of Veyonda® and 177Lu-PSMA

A Rare QoL Study That Could Change Practice : Two drugs comparably improve survival in the treatment of men with hormone-sensitive prostate cancer, so researchers looked at quality of life to see whether that was a difference maker.

Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC : Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.

Multi-phasic 68Ga-PSMA PET/CT in detection of early recurrence in prostate cancer patients with PSA < 1 ng/ml: a prospective study of 135 cases.

PET Spots Prostate Cancer Mets Missed on CT, MRI | MedPage Today : Antigen-targeted tracer highlighted metastases in 27% of 'localized' cases

Impact of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial - ScienceDirect : Early and accurate localisation of lesions in patients with biochemical recurrence (BCR) of prostate cancer may guide salvage therapy decisions. The p…

Stalling Need for ADT in Recurrent Prostate Cancer | MedPage Today : More evidence of benefits with metastasis-directed therapy but overall survival data remain elusive

New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy — BioPortfolio.com : From BioPortfolio: SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that...

The sexual side effects after prostate cancer treatment : I hope that one day, he will arrive at the clinic again, with or without an appointment, and I can close the loop on what he decided and provide him with support, education, and perhaps even help.  But so far, I am left wondering.

Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-... : Clinical Nuclear Medicine : ) of patients treated with 4 to 6 cycles by 177Lu-PSMA inhibitor RLT, retrospectively, and to evaluate the findings extensively in order to determine the critical organ radiation-absorbed limitations and the number of prospective RLT. Materials and Methods A total of 51 cycles 177Lu-PSMA inhibitor RLT in 10 patients was analyzed. Therapies have been applied in 4 to 6 cycles with 8 to 10 weeks' intervals. Dosimetric estimates of kidneys, parotid glands, submandibular glands, and lacrimal glands have been calculated based on MIRD scheme pamphlet no. 16. Regions of interest were drawn with GE Xeleris Functional Imaging Workstation. OLINDA/EXM 1.1 simulation software was used to calculate radiation-absorbed doses. Results Mean radiation-absorbed doses were 0.70 ± 0.24 Gy/GBq for kidneys, 1.34 ± 0.78 Gy/GBq for parotid glands, 0.94 ± 0.45 Gy/GBq for submandibular glands, and 2.28 ± 1.29 Gy/

Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45% | Business Wire : New study of 6,000+ Medicare patients with advanced prostate cancer shows adding PROVENGE (sipuleucel-T) to treatment reduced risk of death by 45%.

Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI | Prostate Cancer and Prostatic Diseases : Prostate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment. We performed a review of the literature to provide a summary of the oncological and functional outcomes of men receiving primary prostate focal therapy. Furthermore, we discuss the impact of the routine implementation of mpMRI as part of the initial prostate cancer diagnostic pathway on the selection of

Abiraterone acetate treatment lowers 11-oxygenated androgens in: European Journal of Endocrinology - Ahead of print

Extended pelvic lymph‐node dissection is independently associated with improved overall survival in prostate cancer patients at high‐risk for lymph‐node invasion - Sood - - BJU International - Wiley Online Library : It is generally agreed upon that extended pelvic lymph‐node dissection (ePLND) provides valuable staging information and helps guide adjuvant therapy, and should be undertaken in prostate cancer (CaP...

3 Keys to Prostate Cancer Care: Clarify, Classify, Personalize : The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers.

GU Oncology Symposium starts today in San Francisco | THE "NEW" PROSTATE CANCER INFOLINK : So the annual ASCO Genitourinary Cancers Symposium will start this morning in San Francisco. For those who are interested, the abstracts of all the presentations to be give (oral and posters) are a…

Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI | Prostate Cancer and Prostatic Diseases : Prostate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment. We performed a review of the literature to provide a summary of the oncological and functional outcomes of men receiving primary prostate focal therapy. Furthermore, we discuss the impact of the routine implementation of mpMRI as part of the initial prostate cancer diagnostic pathway on the selection of

Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities | SpringerLink : Multiparametric magnetic resonance imaging (mpMRI) has been increasingly used to diagnose clinically significant prostate cancer (csPC) because of its usefulness in combination with anatomic and...

The era of the digital natives is approaching: Insights into online peer-to-peer support for persons affected by prostate cancer | SpringerLink

Prostatepedia Weekly 2.8.2020

Interactive Decision Aid for Men Diagnosed With Prostate Cancer - Full Text View - ClinicalTrials.gov : Interactive Decision Aid for Men Diagnosed With Prostate Cancer - Full Text View.

New Treatment Indications Boost Survival in Metastatic Hormone-Sensitive Prostate Cancer : William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.

What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing - Greenberg - - The Prostate - Wiley Online Library : Background Guidelines have changed recently to include genetic counseling (GC) and/or genetic testing (GT) for all men with aggressive prostate cancer (PCa). This study aimed to identify what inform...

Prostate Cancer Mortality: Groups Squabble Over ACS Forecast | Medpage Today : But advocates agree on one thing: pendulum may have swung too far on PSA testing

Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer. | Cancer Research : Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well as in patients previously exposed to chemotherapy. However, resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported. Thus, reliable and integrated preclinical models are required to elucidate the mechanisms of resistance and to assess therapeutic settings that may delay or prevent the onset of resistance. In this study, the prostate cancer (PCa) multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize in vitro and in vivo the response and resistance to enzalutamide. The therapeutic profile as well as the resistance onset were characterized and a multiscale stochastic mathematical model

What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing - Greenberg - - The Prostate - Wiley Online Library : Background Guidelines have changed recently to include genetic counseling (GC) and/or genetic testing (GT) for all men with aggressive prostate cancer (PCa). This study aimed to identify what inform...

Cancer death rates are going down. Is prostate cancer an exception? | Duluth News Tribune : Confusion about PSA screening may be a factor, experts say.

Can cancer treatment cause bone loss? | MD Anderson Cancer Center : Bone loss is a common side effect of aging, but for cancer patients the process can happen at any time. Sonali Thosani, M.D., explains which patients are most at risk of developing bone loss -- and how to keep bones healthy.

Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL

Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer

GIFTS Study for Prostate Cancer - Full Text View - ClinicalTrials.gov : GIFTS Study for Prostate Cancer - Full Text View.

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 - European Urology : At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here.

Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial | SpringerLink : Purpose To determine the start exercise prescription dose in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving second-line hormone treatment and recommended phase II exercise...

Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer | Prostate Cancer and Prostatic Diseases : Androgen deprivation therapy (ADT) in men with prostate cancer (PCa) results in adverse effects, including reduced muscle strength and physical function, potentially compromising daily functioning. We examined whether it was more efficacious to commence exercise at the onset of ADT rather than later in treatment to counter declines in strength and physical function. One-hundred-and-four men with PCa (68.3 ± 7.0 years) initiating ADT were randomised to immediate exercise (IMX, n = 54) or delayed exercise (DEL, n = 50) for 12 months. IMX comprised 6 months of supervised resistance/aerobic/impact exercise initiated at the onset of ADT with a 6-month follow-up. DEL comprised 6 months of usual care followed by 6 months of resistance/aerobic/impact exercise. Upper and lower body muscle strength and physical function were assessed at baseline, 6 and

Cancer Progress and Priorities: Prostate Cancer | Cancer Epidemiology, Biomarkers & Prevention : Prostate cancer is the second most common cancer globally among men, although incidence and mortality rates vary greatly between countries and there are large disparities in prostate cancer incidence and mortality within countries. Despite the high burden of this disease, epidemiologic studies have

More Radium-223 in mCRPC Means More Toxicity | Medpage Today : Similar efficacy and fewer grade 3 events with standard dose

Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA &lt; 1 ng/ml external validation on a single institution database | SpringerLink : Purpose To perform an external validation of a recently published nomogram aimed to predict positive 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence (BCR) after radical prostatectomy (RP)...

Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer | SpringerLink : Immunotherapy is considered as an effective method for cancer treatment owing to the induction of specific and long-lasting anti-cancer effects. Immunotherapeutic strategies have shown significant...

A safer alternative approach to treat aggressive prostate cancer found – Science Chronicle : A multi-institutional team led by IIT Kanpur has found the mechanism responsible for the aggressive return of prostate cancer in treated patients. They also found that treating prostate cancer cell…

Proportion and Incidence of Prostate Cancer May Increase with Age | Cancer Network : Given these data, the researchers indicated that physicians screening for this cancer type should account for strong age dependence.

Shifting the Curtain—Can We Make Sense of the Whole Pelvis Controversy? - International Journal of Radiation Oncology • Biology • Physics : It is one of the classic debates in our field—the role of elective whole pelvis irradiation for high-risk localized prostate cancer. Fed by conflicting data and strong opinions, we await a resolution with the publication of Radiation Therapy Oncology Group (RTOG) 0924, comparing whole pelvis (WP) versus prostate only (PO) radiation therapy (RT) in unfavorable intermediate and favorable high-risk prostate cancer, anticipated for 2021.